Vanguard Group’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $93.1M | Buy |
2,297,354
+70,759
| +3% | +$2.87M | ﹤0.01% | 1856 |
|
|
2025
Q1 | $114M | Buy |
2,226,595
+111,433
| +5% | +$5.72M | ﹤0.01% | 1740 |
|
|
2024
Q4 | $117M | Buy |
2,115,162
+17,839
| +0.9% | +$988K | ﹤0.01% | 1806 |
|
|
2024
Q3 | $69M | Buy |
2,097,323
+107,630
| +5% | +$3.54M | ﹤0.01% | 2048 |
|
|
2024
Q2 | $54.1M | Buy |
1,989,693
+163,061
| +9% | +$4.43M | ﹤0.01% | 2114 |
|
|
2024
Q1 | $66.4M | Buy |
1,826,632
+231,131
| +14% | +$8.4M | ﹤0.01% | 2047 |
|
|
2023
Q4 | $32.3M | Buy |
1,595,501
+43,699
| +3% | +$885K | ﹤0.01% | 2373 |
|
|
2023
Q3 | $27.6M | Buy |
1,551,802
+316,128
| +26% | +$5.62M | ﹤0.01% | 2411 |
|
|
2023
Q2 | $22.3M | Buy |
1,235,674
+10,133
| +0.8% | +$183K | ﹤0.01% | 2542 |
|
|
2023
Q1 | $15.4M | Buy |
1,225,541
+13,071
| +1% | +$164K | ﹤0.01% | 2713 |
|
|
2022
Q4 | $17.8M | Buy |
1,212,470
+276,821
| +30% | +$4.06M | ﹤0.01% | 2673 |
|
|
2022
Q3 | $16M | Buy |
935,649
+279,826
| +43% | +$4.79M | ﹤0.01% | 2728 |
|
|
2022
Q2 | $9.58M | Buy |
655,823
+197,007
| +43% | +$2.88M | ﹤0.01% | 3011 |
|
|
2022
Q1 | $7.72M | Sell |
458,816
-374
| -0.1% | -$6.29K | ﹤0.01% | 3289 |
|
|
2021
Q4 | $10.3M | Buy |
459,190
+30,200
| +7% | +$680K | ﹤0.01% | 3183 |
|
|
2021
Q3 | $9.25M | Buy |
428,990
+2,945
| +0.7% | +$63.5K | ﹤0.01% | 3287 |
|
|
2021
Q2 | $12.3M | Buy |
426,045
+153,055
| +56% | +$4.44M | ﹤0.01% | 3104 |
|
|
2021
Q1 | $8.8M | Buy |
272,990
+2,099
| +0.8% | +$67.7K | ﹤0.01% | 3222 |
|
|
2020
Q4 | $11.2M | Buy |
+270,891
| New | +$11.2M | ﹤0.01% | 2935 |
|